Literature DB >> 27833665

Mitochondria-targeted fluorescent polymersomes for drug delivery to cancer cells.

P S Kulkarni1, M K Haldar1, M I Confeld2, C J Langaas2, X Yang1, S Y Qian1, S Mallik1.   

Abstract

Mitochondria is an attractive target to deliver anticancer drugs. We have synthesized a cationic triphenylphosphonium ion conjugated fluorescent polymer which self-assembles into nanosized polymersomes and targets the encapsulated anticancer drug doxorubicin to cancer cell mitochondria.

Entities:  

Year:  2016        PMID： 27833665      PMCID： PMC5098558          DOI： 10.1039/C6PY00623J

Source DB:  PubMed          Journal:  Polym Chem        ISSN： 1759-9954            Impact factor:   5.582


  17 in total

1.  Biodegradable and pH-sensitive polymersome with tuning permeable membrane for drug delivery carrier.

Authors:  Min Sang Kim; Doo Sung Lee
Journal:  Chem Commun (Camb)       Date:  2010-05-12       Impact factor: 6.222

Review 2.  Stimuli-responsive polymersomes for programmed drug delivery.

Authors:  Fenghua Meng; Zhiyuan Zhong; Jan Feijen
Journal:  Biomacromolecules       Date:  2009-02-09       Impact factor: 6.988

Review 3.  Targeting lipophilic cations to mitochondria.

Authors:  Michael P Murphy
Journal:  Biochim Biophys Acta       Date:  2008-04-08

Review 4.  Polymersomes.

Authors:  Dennis E Discher; Fariyal Ahmed
Journal:  Annu Rev Biomed Eng       Date:  2006       Impact factor: 9.590

Review 5.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.

Authors:  Michael T Lin; M Flint Beal
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

Review 6.  Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance.

Authors:  A Dorward; S Sweet; R Moorehead; G Singh
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

Review 7.  Nanoparticle-based theranostic agents.

Authors:  Jin Xie; Seulki Lee; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2010-08-04       Impact factor: 15.470

8.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

9.  Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs.

Authors:  Neil Ashley; Joanna Poulton
Journal:  Biochem Biophys Res Commun       Date:  2008-11-24       Impact factor: 3.575

Review 10.  Targeting antioxidants to mitochondria by conjugation to lipophilic cations.

Authors:  Michael P Murphy; Robin A J Smith
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820
View more
  2 in total

Review 1.  Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.

Authors:  Ghazal Nabil; Ketki Bhise; Samaresh Sau; Mohamed Atef; Hossny A El-Banna; Arun K Iyer
Journal:  Drug Discov Today       Date:  2018-08-16       Impact factor: 7.851

Review 2.  Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.

Authors:  Jacek Zielonka; Joy Joseph; Adam Sikora; Micael Hardy; Olivier Ouari; Jeannette Vasquez-Vivar; Gang Cheng; Marcos Lopez; Balaraman Kalyanaraman
Journal:  Chem Rev       Date:  2017-06-27       Impact factor: 60.622
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.